Additional Relevant Details Blueprint Medicines announced that the company has entered into a definitive agreement under which it will acquire Lengo Therapeutics, a privately held precision oncology company, for $250M in cash plus up to $215M in additional potential payments based on the achievement of certain regulatory approval and sales-based milestones. The acquisition includes Lengo Therapeutics' lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer, NSCLC, in patients with EGFR exon 20 insertion mutations. Preclinical data show LNG-451 potently inhibits all common EGFR exon 20 insertion variants with marked selectivity over wild-type EGFR and off-target kinases. Based on these and other preclinical data, Lengo Therapeutics anticipates it will submit an investigational new drug application for LNG-451 to the U.S. Food and Drug Administration in December 2021. "Our acquisition of Lengo Therapeutics deepens our commitment to advancing precision oncology therapies and specifically expands our opportunity to transform treatment for patients with EGFR-driven lung cancer," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "The Lengo team has done tremendous work in designing a highly selective therapeutic candidate tailored to the needs of patients with EGFR exon 20 lung cancer, including features with the potential to enable treatment or prevention of brain metastases. With our integrated precision therapy research, development and commercial capabilities, Blueprint Medicines is perfectly positioned to carry forward this compound into the clinic and deliver on our goal to meaningfully advance care for NSCLC patients with EGFR exon 20 insertion mutations." With the addition of LNG-451, Blueprint Medicines will have three investigational compounds that cover the majority of all activating mutations in EGFR, the second most common oncogenic driver in NSCLC. Blueprint Medicines anticipates the acquisition will close in the fourth quarter of 2021, subject to certain conditions.